Hosted on MSN1mon
Experimental drug BNC210 shows early benefits in PTSD trialBionomics Limited is reporting that their experimental drug BNC210, a novel α7 nicotinic acetylcholine receptor modulator, significantly reduced symptom severity in patients with post-traumatic ...
When nicotine enters the brain, it binds to nicotinic acetylcholine receptors (nAChRs) on the surface of neurons. Usually bound to by the neurotransmitter acetylcholine, activation of these excitatory ...
Results that may be inaccessible to you are currently showing.
Hide inaccessible results